First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

0Tip RSCInsights

Authors

Arjun Balar•Stephen Keefe14 more•Joaquim Bellmunt

Journal

The Lancet Oncology

Published

September 26, 2017

Supporters

Support the authors with ResearchCoin

Tip RSC

Topics

Oncology

Medicine

Internal Medicine

Response Evaluation Criteria In Solid Tumors

Cisplatin

Show all topics

DOI

10.1016/s1470-2045(17)30616-2

License

Unknown License